OP43L
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1)
lyophilized, clone DO-1, Calbiochem®
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
NACRES:
NA.43
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
DO-1, monoclonal
Postać
lyophilized
nie zawiera
preservative
reaktywność gatunkowa
feline, human
spodziewany brak reakcji z
mouse, rat
producent / nazwa handlowa
Calbiochem®
warunki przechowywania
OK to freeze
izotyp
IgG2a
Warunki transportu
ambient
temp. przechowywania
2-8°C
docelowa modyfikacja potranslacyjna
unmodified
informacje o genach
human ... TP53(7157)
Opis ogólny
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Gel Shift, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).
Immunogen
Epitope: Within amino acids 21-25 of human p53
Human
wild type, recombinant, human p53
Zastosowanie
Frozen sections (1 µg/ml; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Ostrzeżenie
Toxicity: Standard Handling (A)
Postać fizyczna
Lyophilized from a volatile buffer, 100 µg BSA.
Rekonstytucja
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Reconstituted product will be more stable if 0.1% sodium azide is added (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least two hours. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage.
Komentarz do analizy
Negative Control
SK-OV-3 cells or normal skin tissue
SK-OV-3 cells or normal skin tissue
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Inne uwagi
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, resuspend in 100 µl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
Informacje prawne
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 1
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Darren M Hutt et al.
Methods in molecular biology (Clifton, N.J.), 1510, 77-91 (2016-10-21)
Gene expression is regulated in part through the reversible acetylation of histones, by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC). HAT activity results in the addition of acetyl groups on the lysine residues of histone tails leading
E E Hoskins et al.
Oncogene, 27(35), 4798-4808 (2008-04-29)
Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and
Yan Degenhardt et al.
Molecular cancer therapeutics, 9(7), 2079-2089 (2010-06-24)
Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified by comparing the genomics and genetics of a panel of
H Takahashi et al.
Oncogene, 36(30), 4267-4276 (2017-03-28)
L-asparaginase has been used for more than three decades in acute lymphoblastic leukemia (ALL) patients and remains an essential drug in the treatment of ALL. Poor response to L-asparaginase is associated with increased risk of therapeutic failure in ALL. However
Kristina Heyne et al.
Cell cycle (Georgetown, Tex.), 12(15), 2479-2492 (2013-07-11)
The inflammation regulating transcription factor NFκB and the tumor-suppressing transcription factor p53 can act as functional antagonists. Chronic inflammation (NFκB activity) may contribute to the development of cancer through the inhibition of p53 function, while, conversely, p53 activity may dampen
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej